GlassScriptPhysician profile
Narendra Kutnikar
NPI 1497742175
$6,301.64
in general payments reported to CMS, 2019-2025
32 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $1,163 · 2021: $1,270 · 2022: $988 · 2023: $979 · 2024: $738 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906 · Education: $26.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.42 |
| Education | $26.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,063.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $808.79 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $752.09 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $625.85 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $545.25 | 2022-2024 | |
| Lilly USA, LLC | $494.87 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.86 | 2019-2025 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $378.79 | 2019-2022 | |
| Pfizer INC. | $209.12 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $194.87 | 2019-2023 | Verquvo |
| Abbott Laboratories | $163.98 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.01 | 2019-2024 | Xifaxan |
| Allergan, INC. | $56.19 | 2019-2020 | |
| Esperion Therapeutics, INC. | $54.23 | 2022-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $52.69 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $50.82 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $38.12 | 2021 | |
| Horizon Therapeutics Plc | $34.28 | 2020 | |
| Nestle Healthcare Nutrition INC. | $33.43 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $26.96 | 2023 | |
| Eisai INC. | $24.15 | 2020 | |
| Exact Sciences Corporation | $22.89 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $19.79 | 2022 | |
| Philips North America LLC | $19.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.78 | 2022 | |
| Biodelivery Sciences International, INC. | $18.64 | 2021 | |
| Insulet Corporation | $17.94 | 2024 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $14.88 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.62 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.37 | 2024 | Nuzyra |
| Corcept Therapeutics | $12.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Kutnikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.